Vimeo
LinkedIn
Instagram
Share |

Alternatives

Private Equity is mainstream among ultra-high-net-worth (94% engaged), with the bulk looking for enhanced returns (67%).

Private Equity is mainstream among ultra-high-net-worth (94% engaged), with the bulk looking for enhanced returns (67%).

In an exclusive interview with Campden FB, 19th-Generation family member George Muthoot George of the Muthoot Group talks about living up to family legacy, a passion for hospitality and the ultimate motivation for sustainable investment…

In an exclusive interview with Campden FB, 19th-Generation family member George Muthoot George of the Muthoot Group talks about living up to family legacy, a passion for hospitality and the ultimate motivation for sustainable investment…

In this week’s FB Roundup, Israeli billionaire David Fattal buys Brighton’s Grand Hotel; Sanjeev Gupta’s GFG Alliance aims to rescue collapsed UK steel companies; and tributes are paid to baseball team owner Ted Lerner.

In this week’s FB Roundup, Israeli billionaire David Fattal buys Brighton’s Grand Hotel; Sanjeev Gupta’s GFG Alliance aims to rescue collapsed UK steel companies; and tributes are paid to baseball team owner Ted Lerner.

A beneficiary of the sale of her family’s multi-generational pharmaceutical companies, Victoria Engelhorn was determined to take the opportunity to grow, realise her own dreams and give back to society. In an exclusive interview with Campden FB, she reveals how forging her own socially responsible path gave her meaning and purpose.

A beneficiary of the sale of her family’s multi-generational pharmaceutical companies, Victoria Engelhorn was determined to take the opportunity to grow, realise her own dreams and give back to society. In an exclusive interview with Campden FB, she reveals how forging her own socially responsible path gave her meaning and purpose.

As a seasoned Tech Bio investor, Hanadi Jabado understands more than most the importance and implications of using data to transform drug discovery and positively change patient outcomes. Here, she talks to Campden FB about starting the medical and cost-efficient benefits of Tech Bio and the rising importance of ‘data donation’…

As a seasoned Tech Bio investor, Hanadi Jabado understands more than most the importance and implications of using data to transform drug discovery and positively change patient outcomes. Here, she talks to Campden FB about starting the medical and cost-efficient benefits of Tech Bio and the rising importance of ‘data donation’…

Click here >>
Close